• Corpus ID: 37382491

Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.

@article{Scheuch2007AnticoagulativeEO,
  title={Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.},
  author={Gerhard Scheuch and Peter Brand and T. Meyer and C. Herpich and Bernhard M{\"u}llinger and Joachim Brom and Gottfried Weidinger and Martin Kohlh{\"a}ufl and Karl H{\"a}ussinger and Michael Spannagl and Wolfgang Schramm and Ruediger Siekmeier},
  journal={Journal of physiology and pharmacology : an official journal of the Polish Physiological Society},
  year={2007},
  volume={58 Suppl 5 Pt 2},
  pages={
          603-14
        }
}
  • G. Scheuch, P. Brand, R. Siekmeier
  • Published 1 November 2007
  • Medicine, Biology
  • Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Inhalation of heparin results in local antiinflammatory and antifibrotic effects and an inhibition of blood coagulation. A number of experimental and clinical studies demonstrated that inhalant administration of heparin or low molecular weight heparin (LMWH) is a feasible and save tool for anticoagulative treatment. However, heparin and LMWH differ in respect to their molecular weight, pulmonary absorption, and principle of their anticoagulative pattern. In our study we investigated the… 
Anticoagulant effects of inhaled unfractionated heparin in the dog as determined by partial thromboplastin time and factor Xa activity.
TLDR
Even at doses higher than those known to be effective in people, inhaled heparin appears to have no detectable local or systemic anticoagulant effects in dogs with the current delivery method.
Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis.
TLDR
Inhaled heparin appears to be safe and well tolerated in IPF patients, and median lung function values, exercise capacity, and quality of life scores appeared largely unaltered.
Low molecular weight heparins and their clinical applications.
Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies
Introduction: Several low-molecular-weight heparins are available for the prevention and treatment of venous thromboembolism and arterial thrombosis. Certoparin has been extensively tested in
Inhalational use of antithrombotics in humans: Review of the literature.
Pharmacological and clinical application of heparin progress: An essential drug for modern medicine.
Targeting Drugs to the Lungs – The Example of Insulin
TLDR
In the last three decades methods for recombinant synthesis of peptides and proteins were developed allowing the production of large amounts of these substances for clinical treatment, making the lung to an important target for inhalative administration of drugs with systemic mode of action.
Treatment of systemic diseases by inhalation of biomolecule aerosols.
  • R. Siekmeier, G. Scheuch
  • Medicine, Biology
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • 2009
TLDR
This review describes some examples other than insulin in the field of inhalant treatment of systemic diseases that have been introduced in clinical treatment for a short time and a lot of other molecules have been tested in aerosol inhalation studies.
Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials
TLDR
This review summarises principles and advances of individualised controlled inhalation (ICI) as offered by the AKITA® inhalation system.
...
...